92260-32-7

Basic information

• Product Name: 6-BROMO-2,3-DIMETHYL-3H-IMIDAZO[4,5-B]PYRIDINE
• Synonyms: 6-BROMO-2,3-DIMETHYL-3H-IMIDAZO[4,5-B]PYRIDINE;-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine
• CAS NO: 92260-32-7
• Molecular Formula: C₈H₈BrN₃
• Molecular Weight: 226.07322
• Mol File: 92260-32-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-BROMO-2,3-DIMETHYL-3H-IMIDAZO[4,5-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2,3-DIMETHYL-3H-IMIDAZO[4,5-B]PYRIDINE(92260-32-7)
• EPA Substance Registry System: 6-BROMO-2,3-DIMETHYL-3H-IMIDAZO[4,5-B]PYRIDINE(92260-32-7)

Safety Data

• Hazardous Substances Data: 92260-32-7(Hazardous Substances Data)

Upstream product

• 41231-05-4 2,3-Dimethylimidazo<4,5-b>pyridine 
• 1445-45-0 Trimethyl orthoacetate 
• 89415-54-3 5-bromo-N²-methylpyridine-2,3-diamine 
• 78-39-7 Triethyl orthoacetate 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 70232-59-6 5-bromo-N-methyl-3-nitropyridin-2-amine 
• 42869-47-6 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine 
• 74-88-4 methyl iodide 

Relevant articles and documents

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

INHIBITORS OF HIV REPLICATION

Compounds of formula (I): wherein R1, R2, A1, A2, A3, A4, X and Y are as defined herein, are useful as inhibitors of HIV replication.

Halogenation of 2-unsubstituted and 2-methylimidazo[4,5-b]pyridine derivatives

Halogenation of 2-unsubstituted and 2-methylimidazo[4,5-b]pyridines and their N-methyl derivatives with bromine and chlorine in acetic acid takes different pathways, depending on the acetic acid concentration. The bromination in 50% aqueous acetic acid gives only 6-bromoimidazo[4,5-b]pyridines; bromination and chlorination of 2-unsubstituted imidazo[4,5-b]pyridines in glacial acetic acid leads to 5,6-dibromo(dichloro)imidazo[4,5-b]pyridin-2-ones, and bromination of 2-methylimidazo[4,5-b]pyridines in glacial acetic acid involves both the pyridine ring and the 2-methyl group to afford the corresponding 6-bromo-2-tribromomethylimidazo[4,5-b]pyridines.